Clovis oncology, inc. (CLVS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Operating activities
Net loss

-413,335

-400,424

-400,182

-395,974

-376,736

-368,009

-320,633

-291,433

-365,627

-346,397

-365,242

-370,272

-324,201

-349,137

-397,950

-430,900

-373,117

-352,861

-288,227

-229,224

-192,457

-160,031

-134,327

-115,005

-99,582

-84,532

-76,388

-74,336

-70,652

-73,983

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense

53,625

54,304

53,123

50,091

50,817

49,090

50,221

51,912

47,673

44,707

42,253

38,817

37,778

39,796

40,643

43,847

42,640

40,357

35,390

28,420

25,263

21,517

18,427

15,782

12,677

9,505

8,004

6,707

5,767

4,949

0

0

0

Depreciation and amortization

8,176

7,768

7,831

6,726

5,737

4,601

3,090

2,730

2,451

2,504

2,233

1,872

1,510

1,141

1,032

960

862

761

-2,708

-2,762

-2,864

444

3,765

3,684

3,665

250

269

300

331

353

0

0

0

Amortization of premiums and discounts on available-for-sale securities

1,532

1,521

1,003

232

-1,387

-1,345

-1,427

-802

31

-354

-27

-305

-345

-211

-271

-576

-1,009

-1,400

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

2,999

2,858

2,712

2,607

2,497

2,178

1,859

1,539

1,288

1,279

1,270

1,261

1,252

1,242

1,233

1,223

1,214

1,205

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Write-off of debt issuance costs related to convertible senior notes conversion

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on convertible senior notes conversion

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-105

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent purchase consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-24,661

-52,421

-51,575

-23,949

-27,792

-3,024

-5,597

-6,971

-3,301

0

0

0

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

-3,259

-3,218

-854

170

-27,686

-31,771

0

0

0

-

-

-

-

761

0

0

0

-

-

-

-

-

-

-

-

Amortization of premiums and discounts on available for sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities:
Accounts receivable

8,832

7,518

2,345

3,076

3,158

3,371

11,160

7,824

7,222

6,061

0

1,144

2,378

121

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-4,615

26,160

47,869

50,033

32,156

49,936

47,703

56,573

62,720

27,508

5,345

6,478

6,504

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid and accrued research and development expenses

-14,237

-23,233

-21,048

-14,084

-11,945

-9,145

-377

2,033

6,613

17,297

16,771

17,754

17,810

15,364

21,801

8,679

1,255

-14,122

-32,006

-23,118

-20,157

-18,112

-8,438

-8,464

-10,273

-3,276

-1,900

-906

-463

-2,993

0

0

0

Deposit on inventory

0

-

-

-

-

12,350

12,816

53,937

-8,933

20,461

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other operating assets and liabilities

-3,262

6,837

6,506

9,834

11,761

8,750

9,827

-26,498

9,589

6,476

5,475

37,076

-2,392

-1,039

-1,478

362

3,705

4,380

469

2,141

1,252

910

4,931

2,643

1,654

995

595

427

142

17

0

0

0

Accounts payable

10,916

12,289

3,389

3,517

12,889

5,770

5,352

3,295

-9,873

5,637

3,828

-1,950

9,554

-1,544

1,659

9,375

6,559

8,105

6,644

3,056

5,083

-1,369

532

-374

-2,767

958

-1,288

142

1,323

-758

0

0

0

Other accrued expenses

14,167

13,322

7,489

-11,310

-1,868

4,290

3,303

16,292

18,012

6,556

8,893

10,763

1,861

7,867

5,609

4,228

4,597

5,295

3,599

5,910

2,506

3,882

-391

-1,419

-2,040

-1,202

426

321

434

-93

0

0

0

Net cash used in operating activities

-307,658

-323,615

-336,195

-351,641

-363,813

-365,997

-348,848

-322,207

-281,100

-260,904

-250,001

-264,551

-263,381

-266,680

-287,694

-299,105

-288,399

-253,066

-211,327

-173,803

-145,922

-117,051

-106,935

-88,304

-76,763

-71,712

-66,511

-65,225

-61,314

-65,384

0

0

0

Investing activities
Purchases of property and equipment

2,093

3,290

4,366

8,518

10,256

9,242

7,834

2,446

651

487

421

259

215

766

2,621

2,785

2,823

3,035

1,270

1,383

2,882

2,286

2,232

1,964

294

121

100

216

404

1,058

0

0

0

Deposits for sale of property and equipment

-

-

-

-

-

-

-

-

-

2,515

2,580

2,515

2,515

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of available-for-sale securities

331,382

459,835

0

0

0

-

-

-

-

263,500

180,000

180,000

133,000

0

0

250,324

250,324

392,540

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Sales of available-for-sale securities

548,301

621,998

675,097

586,845

443,500

300,000

105,000

173,500

173,500

213,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

2,000

0

0

0

Acquired in-process research and development - milestone payment

-

15,750

0

0

0

-

-

-

-

1,100

1,100

1,100

1,100

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

214,351

143,398

140,152

-18,202

-275,171

-264,242

-361,334

-92,446

42,349

-54,102

54,464

-33,809

88,235

199,299

172,445

-12,112

-87,150

-254,578

-252,814

-143,599

-145,098

-2,286

-12,145

-11,877

-10,207

-10,034

-100

-216

-404

942

0

0

0

Financing activities
Proceeds from the sale of common stock, net of issuance costs

0

-

-

-

-

-

-

-

-

545,838

545,838

546,170

221,224

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Payment of convertible senior notes

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from borrowings under financing agreement

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options and employee stock purchases

2,175

3,266

3,296

3,856

4,546

3,967

5,015

6,560

11,077

16,237

16,993

15,503

10,145

5,176

3,546

4,841

5,483

5,971

5,427

3,473

2,299

1,163

1,131

1,166

1,742

1,771

1,676

1,641

391

315

0

0

0

Payments on finance leases

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on other long-term liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

133,439

119,888

107,172

10,426

389,043

388,464

389,792

391,017

335,691

562,075

562,831

561,673

231,369

5,176

3,546

303,350

303,992

304,480

303,914

281,786

280,612

279,476

279,466

1,091

260,813

260,842

260,747

260,787

70,386

70,291

0

0

0

Effect of exchange rate changes on cash and cash equivalents

-131

286

-501

-297

-865

-547

-229

171

1,125

943

454

94

-547

-365

-16

-15

388

-757

-915

-1,355

-1,704

-690

-425

82

177

35

9

-9

-17

12

0

0

0

Increase (decrease) in cash and cash equivalents

40,001

-60,043

-89,372

-359,714

-250,806

-242,322

-320,619

-23,465

98,065

248,012

367,748

263,407

55,676

-62,570

-111,719

-7,882

-71,169

-203,921

-161,142

-36,971

-12,112

159,449

159,961

-99,008

174,020

179,131

194,145

195,337

8,651

5,861

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

11,052

10,515

8,640

11,063

9,188

9,188

9,188

7,188

7,188

7,188

7,188

7,188

7,188

7,188

7,188

7,187

7,187

7,307

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Vesting of restricted stock units

7,626

5,442

5,413

6,734

7,676

10,808

12,851

17,900

16,045

12,170

9,467

2,768

2,709

175

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets recorded for which payment (has)/has not yet occurred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0